Deciphering B and T cell Co-stimulation for the Targeted Treatment of IgG4-Related Disease

Status

Recruiting

Phases

Phase 2

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2024-512863-30-00

Enrollment

Registered

2024-04-16

Start date

2024-12-09

Completion date

Unknown

Last updated

2024-04-16

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

IgG4-related disease

Brief summary

Reduction of disease recurrence in patients with IgG4-related disease treated with abatacept compared with placebo-treated pazineti

Interventions

DRUGABATACEPT

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Design outcomes

Primary

Measure	Time frame
Reduction of disease recurrence in patients with IgG4-related disease treated with abatacept compared with placebo-treated pazineti	—

Countries

Italy

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 4, 2026